

1 **Comparison of mechanical homogenization versus enzymatic digestion sample preparation**
2 **methodologies for SARS-CoV-2 detection in saliva for surveillance of variants of concern**
3 **on the University of Tennessee campus in early 2021.**

4 **(Short Title:** Comparison of three detection methods for SARS-CoV-2 variants from saliva)

5 Magen R. Poindexter¹, Tingting Xu¹, Cynthia M. Swift^{1,5}, Caleb M Proctor⁶, Fadime Kara-
6 Murdoch^{1,5,10}, Zachary P Morehouse^{6,7,8}, Gabriella L Ryan⁶, Frank E. Löffler^{1,2,3,4,5}, Rodney J
7 Nash^{6,8,9,*}

8 **Affiliations:**

- 9 1. Center for Environmental Biotechnology, University of Tennessee, Knoxville, TN,
10 United States
- 11 2. Department of Microbiology, University of Tennessee, Knoxville, TN, United States
- 12 3. Department of Civil and Environmental Engineering, University of Tennessee,
13 Knoxville, TN, United States
- 14 4. Department of Biosystems Engineering and Soil Science, University of Tennessee,
15 Knoxville, TN, United States
- 16 5. Biosciences Division, Oak Ridge National Laboratory, Oak Ridge, TN, United States
- 17 6. Omni International Inc, A PerkinElmer Company, Kennesaw, GA, United States
- 18 7. Michigan State University College of Osteopathic Medicine, East Lansing, MI, United
19 States
- 20 8. Jeevan BioSciences, Tucker, GA, United States
- 21 9. Department of Biology, Georgia State University, Atlanta, GA, United States
- 22 10. Battelle Memorial Institute, Columbus, OH, United States

23 * Corresponding author, Rodney Nash, rnash@omni-inc.com

24

25 Notice: This manuscript has been authored by UT-Battelle, LLC, under contract DE-AC05-
26 00OR22725 with the US Department of Energy (DOE). The US government retains, and the
27 publisher, by accepting the article for publication, acknowledges that the US government retains
28 a nonexclusive, paid-up, irrevocable, worldwide license to publish or reproduce the published
29 form of this manuscript, or allow others to do so, for US government purposes. DOE will
30 provide public access to these results of federally sponsored research in accordance with the
31 DOE Public Access Plan (<http://energy.gov/downloads/doe-public-access-plan>).

32

33 **Abstract:**

34 The SARS-CoV-2 pandemic has profoundly impacted communities across the globe, requiring
35 accurate and accessible diagnostic technologies in support of public health mitigation efforts. As
36 testing has evolved throughout the course of the pandemic, varying sample preparation
37 methodologies have been employed. Herein we perform a comparison of three commercial
38 sample preparation methods: two mechanical homogenization workflows and one enzymatic
39 digestion approach for the detection of SARS-CoV-2 from biomarker genes in 20 human saliva
40 pools. SARS-CoV-2 variants of concern were also identified on the University of Tennessee,
41 Knoxville campus during the spring semester of 2021 utilizing the commercial PerkinElmer
42 PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit. Two hundred and ten (210) human
43 saliva pools were selected and analyzed for the presence of SARS-CoV-2 variants of concern
44 providing insight into the utility of these various commercial workflows for integration into
45 current public health SARS-CoV-2 surveillance measures.

46 **Keywords:**

47 SARS-CoV-2, variant of concern, diagnostics, sample preparation

48

49 **Introduction:**

50 Accurate and accessible diagnostic testing provides the cornerstone of most public health and
51 treatment efforts for viral disease. The global pandemic caused by SARS-CoV-2 infections
52 required rapid advancement in diagnostic techniques and technologies to maintain pace with the
53 global demand for accurate viral testing [1]. Throughout the pandemic, quantitative polymerase
54 chain reaction (qPCR) based diagnostic assays have been the gold standard for SARS-CoV-2
55 diagnostics [1]. In March 2020, ThermoFisher Scientific commercialized one of the first
56 diagnostics assays for the detection of SARS-CoV-2; a TaqPath COVID-19 qPCR based kit
57 which relies on fluorescence technologies allowing for multiplexing of PCR assays to detect and
58 distinguish between different gene targets in the same sample. The TaqPath COVID-19 qPCR
59 kit was granted emergency use for clinical testing by the FDA on March 13, 2020
60 (<https://www.fda.gov/media/136113/download>). The qPCR based assays developed for SARS-
61 CoV-2 diagnostics have experienced multiple iterations of refinement, evolving from the initial
62 nasopharyngeal swab tests to assays for other sample materials including saliva, wastewater, and
63 feces [2-6]. This rapid diversification of sample inputs for qPCR detection of SARS-CoV-2
64 biomarkers was driven by a necessity to maintain public compliance with testing efforts while
65 maintaining accuracy and availability of testing.

66 As the pandemic progressed, multiple variants of concern emerged across the globe with the
67 potential to evade current diagnostic assays and available treatments [7]. It soon became a
68 priority of many health organizations to identify and track these emerging variants of concern
69 across different geographic areas and populations [8]. Diagnostic assay development became an
70 increasing priority to allow for SARS-CoV-2 variants of concern detection to support public
71 health efforts.

72 In this study, we compare three qPCR based methodologies for SARS-CoV-2 diagnostics using
73 human saliva samples collected on the University of Tennessee, Knoxville campus. Two of these
74 methodologies, the SalivaDirect with Proteinase K and the KingFisher RNA Extraction method,
75 are commercially available and were compared to the Omni Direct-to-PCR (dPCR) method [9-
76 11]. This comparative evaluation provides insight into the ability of different workflows to
77 accurately detect viral RNA within saliva samples. While less invasive for the patient to provide,
78 these samples often have increased PCR inhibitors present, making saliva a more difficult sample
79 to process and achieve sensitive detection of SARS-CoV-2 biomarker genes. Thus, comparative
80 studies assessing the impact of sample preparation workflows are crucial for establishing
81 confidence in diagnostic testing with this sample medium.

82 Additionally, the human saliva samples collected for this study were screened for variants of
83 concern utilizing the commercial PerkinElmer PKamp VariantDetect SARS-CoV-2 RT-PCR
84 Assay kit. These samples were collected throughout the 2021 spring semester, and demonstrated
85 the ability of this kit to accurately detect and differentiate between variants of SARS-CoV-2 as
86 they spread throughout the campus community.

87 **Materials and Methods:**

88 This study assessed the efficacy of the Omni protocol for detection of SARS-CoV-2 RNA in de-
89 identified human saliva samples. The performance of the Omni Direct-to-PCR (dPCR) approach
90 was compared against a standard RNA extraction method (i.e., KingFisher extraction) commonly
91 used in Clinical Laboratory Improvement Amendments (CLIA) certified labs as well as the
92 SalivaDirect protocol developed by the Yale School of Public Health, New Haven, CT [12].
93 The Omni dPCR method utilizes samples homogenized by the Bead Ruptor Elite (Omni, Cat.
94 No. 19-042E) and then added directly to the qPCR reactions. The KingFisher extraction protocol

95 relies upon viral particle lysis and mechanical disruption of the virus. The SalivaDirect protocol
96 combines both Proteinase K and heat treatment to denature human saliva samples.

97 The samples utilized in this study were obtained from the University of Tennessee, Knoxville
98 campus in the Spring 2021 semester. All participants were consented via written and oral consent
99 prior to providing saliva samples. Saliva samples provided for the research in this study were
100 deidentified prior to being handed over to the lab for further use. All research was approved
101 under protocol IBC-20-547-2 approved on July 6 2020 by the UTK institutional review board.

102 In early summer 2020, the University of Tennessee, Knoxville campus developed and validated
103 protocols to detect SARS-CoV-2 for public health surveillance using RT-qPCR assays that target
104 the viral envelope (E), nucleocapsid (N), RNA polymerase (RdRP), and human Ribonuclease P
105 (RNase P, used as a positive control) genes for human saliva under IBC-20-547-2 (IBC-20-547-
106 2; July 6, 2020). The E gene provides for the outermost layer of the virus protecting the genetic
107 material when traveling from one host to another. The N gene provides the protective coat of
108 proteins associating with the viral nucleic acids. The RdRP gene is one of 16 nonstructural
109 proteins that are produced in the overlapping open reading frames (ORF1ab region) that encode
110 for polyproteins PP1ab and PP1a. The function of these nonstructural proteins includes viral
111 transcription, replication, proteolytic processing, suppression of host immunity and host gene
112 expression [13]. The E, N, and RdRP/ORF1ab regions have been the commonly analyzed viral
113 targets for diagnosis.

114 The de-identified human saliva samples used in this study were chosen based upon previous
115 testing using the protocols established by the University of Tennessee SARS-CoV-2 Surveillance
116 Testing Laboratory to include known SARS-CoV-2 positive and known SARS-CoV-2 negative
117 human saliva samples. Table 1 below shows the published primer and probe sets specifically

118 targeting the E, RdRP, and RNase P genes that were used in this study [3, 4, 6]. Although the
119 viral N gene was originally included in the multiplexed qPCR assays during previous testing, it is
120 excluded in this study as both the E and RdRP targets are sufficient for detecting the presence of
121 the viral genome in the saliva samples.

122

Primer or Probe	Primer Sequence (5'-3')	Target	Reference
E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT		[4]
E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	SARS-CoV-2 envelope (E)	[4]
E_Sarbeco_P1	VIC-ACACTAGCCATCCTTACTGCGCTTCG-QSY		[4]
RdRP_Fnew	GTGAAATGGTCATGTGTGGCGG	SARS-CoV-2 RNA polymerase (RdRP)	[6]
RdRP_Rnew	CAAATGTAAAAACACTATTAGCATA		[6]
RdRP_SARSr-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC-QSY	RNA polymerase (RdRP)	[6]
RNase P-F	AGATTTGGACCTGCGAGCG	Human Ribonuclease P (RNase P)	[3]
RNase P-R	GAGCGGCTGTCTCCACAAGT		[3]
RNase P-P	JUN-TTCTGACCTGAAGGCTCTGCGCG-QSY	Ribonuclease P (RNase P)	[3]

123 **Table 1.** Primers and probes used in this study.

124

125 Omni provided a PerkinElmer PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit
126 (PerkinElmer, Cat. No. 4224-0010) to detect and differentiate SARS-CoV-2 variants. The
127 PerkinElmer kit uses different combinations of multiplexed primers and TaqMan probes to detect
128 different SARS-CoV-2 variants (i.e., combination C detects wildtype, Alpha, Beta and Gamma
129 variants and combination F detects Delta and Kappa variants). To demonstrate the utility of this
130 kit, 210 de-identified human saliva pools were used to test the validity and efficacy of this kit.
131 To verify that assay reagents performed according to expectations, the controls used included an
132 extraction control with nuclease free water added instead of a human saliva sample; a no
133 template PCR control with nuclease-free water added instead of RNA during RT-qPCR; and a
134 positive control of 5 μ L of 1.05×10^3 genome copy equivalents/ μ L of RNA from inactivated
135 SARS-CoV-2 (USA-WA1/2020) was added during RT-qPCR (BEI Resources, Cat. No. NR-

136 52286). The PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit detects 4 different SARS-
 137 CoV-2 mutations which include the Alpha variant (B.1.1.7 – United Kingdom, September 2020),
 138 the Beta variant (B.1.351 – South Africa, May 2020), Gama variant (P.1 – Brazil, November
 139 2020), Delta variant (B.1.617 – India, October 2020), and the Kappa variant (B.1.617.1 – India,
 140 April 2021) (Table 3).

141

142 **Experiment 1: Comparison of Sample Processing Method:** Twenty saliva pools each
 143 consisting of five individual human saliva samples were selected including 18 known positive
 144 (+) saliva pools; and 2 known negative (-) saliva pools. TaqPath™ 1-Step Multiplex Master Mix
 145 (No ROX) (ThermoFisher Cat. No. A28523; Waltham, MA) was added to multiplex assays
 146 (Table 2) for the detection of the E gene, the RdRP gene, and the RNase P gene, the latter
 147 serving as an internal amplification control gene. Extraction negative controls were established
 148 by adding sterile water in the place of a saliva pool. RT-qPCR negative controls (no template
 149 control) consisted of complete assays with 5 µL of nuclease-free water replacing the RNA
 150 template. Positive controls for the E and RdRP genes were established by adding 5 µL of
 151 1.05×10^3 genome equivalents/µL synthetic RNA to give a concentration of 5.25×10^3 genome
 152 copy equivalents per reaction (BEI Resources, Cat. No. NR-52286).

Reaction Components	Stock conc. (µM)	Final Conc. (nM) ¹⁵³
Nuclease-free water		154
E_Sarbeco_P1	100	250 155
E_Sarbeco_F1	100	600
E_Sarbeco_R2	100	600 156
RdRP_SARSr-P2	100	250
RdRP_Fnew	100	600 157
RdRP_Rnew	100	600 158
RNase P-P	100	250
RNase P-F	100	600 159
RNase P-R	100	600 160
TaqPath 1-Step Multiplex Master Mix (No ROX)	4X	1X 161
AmpliTaq	5 U/µL	1 U/rxn

162

163 **Table 2.** RT-qPCR reaction multiplex assay mixture used for each of the three processing
 164 methods with the only change being the source of the template.

- 165 1) Omni Direct-to-PCR method: Each human saliva pool (500 μ L) was transferred to a 2-
166 mL Omni bead tube (Omni, Cat. No. 19-628). The bead tubes were placed inside the
167 Bead Ruptor Elite (Omni, Cat. No. 19-042E) and agitated at 4.5 m/s for 30 seconds. Five
168 μ L of each processed pool were used for qPCR.
- 169 2) KingFisher extraction method: The MagMAX™-96 Viral RNA Isolation Kit and kit
170 supplied buffers were used for this extraction method following manufacturer protocol
171 (ThermoFisher, Cat. No. AM1836; Waltham, MA) with the addition of Dithiothreitol
172 (DTT) to lower the viscosity of the saliva. DTT (Sigma-Aldrich, Cat. No. 501656980,
173 Inc., St. Louis, MO) (20 μ L of a 50 mM aqueous stock solution) was added to 200 μ L of
174 each human saliva pool and incubated at room temperature for 30 minutes. After the
175 incubation, Proteinase K (5 μ L of a 1-5% aqueous stock solution; ThermoFisher Cat. No.
176 A42363; Waltham, MA) and 275 μ L binding buffer/bead mix (provided in kit) were
177 added to each sample. The RNA was first washed with wash buffer (provided in kit) and
178 then with 80% molecular grade ethanol, before RNA was eluted in 50 μ L elution buffer
179 (provided by in kit). Five μ L of the RNA extract from each sample were used for qPCR
- 180 3) RNA extraction following SalivaDirect with Proteinase K treatment: Proteinase K (2.5
181 μ L of a 1-5% aqueous stock solution; ThermoFisher Cat. No. A42363; Waltham, MA)
182 was added to 50 μ L of human saliva pool and vortexed for 1 minute. Samples were then
183 heated to 95°C in the Veriti™ 96-well Thermal Cycler (Applied Biosystems, Model No.
184 9902, Waltham, MA) for 5 minutes. Five μ L from each sample were used for qPCR [12].

185

186 **Experiment 2: Variant tracking:** A total of 210 positive human saliva pools collected from
187 September 2020 through April 2021 were subjected to variant testing with the PKamp

188 VariantDetect SARS-CoV-2 RT-PCR Assay kit. These 210 positive human saliva pools were
189 selected based upon previous identification using the multiplex qPCR assay protocol established
190 by the University of Tennessee SARS-CoV-2 Surveillance Testing Laboratory. RNA was freshly
191 extracted from each of the 210 positive human saliva pools using the KingFisher Flex
192 MagMAX™-96 Viral RNA Isolation Kit per manufacturer protocol (ThermoFisher, Cat No.
193 AM1836; Waltham, MA) with the addition of DTT. Immediately following RNA extraction, RT-
194 qPCR was performed using the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit and the
195 corresponding protocols provided by the manufacturer. The PKamp VariantDetect SARS-CoV-2
196 RT-PCR Assay kit combination C (which detects wildtype, Alpha, Beta and Gamma variants)
197 was used to identify variants present in these 210 pools. If combination D testing did not clearly
198 identify the variant present in a pool, that pool was then tested using combination F (which
199 detects Delta and Kappa variants).

200

201 **Results:**

202 Experiment 1 compared the three different human saliva pool processing methods, and the
203 results are shown in Figure 1. The RNase P gene was amplified from all pools using all three
204 processing methods. False positive results were obtained for the E gene in negative pools when
205 the Omni Direct-to-PCR method was used (Figure 1 and Figure 2). These samples were
206 determined to be false positives as they were initially tested following the established protocols
207 by the University of Tennessee SARS-CoV-2 Surveillance Testing Laboratory and were known
208 to be negative for SARS-CoV-2. Of note is the observation that, in a small proportion of the 210
209 human saliva pools, the RdRP gene was not amplified with the assay that targets the ORF1ab

210 region (Figure 1). Amplification of the RdRP gene was only observed in pools processed when
211 the KingFisher extraction method was used.

212
213 **Figure 1.** qPCR assays targeting the E, RdRP and RNase P genes in 20 sample pools plus
214 controls. No amplification occurred in assays targeting the RdRP gene of the ORF1ab region of
215 the RdRP gene of SARS-CoV-2. The negative saliva pools are Pool 1 and Pool 2. Extraction
216 Negative Control (ENC); No Template Control (NTC); Synthetic SARS-CoV-2 RNA (PC).

217
218 **Figure 2.** Representative linear qPCR amplification plots for the E Gene showing false positive
219 amplification seen in SARS-CoV-2-negative samples with RNA extracted using the Omni
220 Direct-to-PCR method. The Omni Direct-to-PCR method using known negative saliva amplifies
221 with a Cq of 31.966, which is earlier than the known positive saliva with a Cq of 33.437. The
222 Positive sample example is Pool 4 and the negative sample is Pool 1.

223
224 Figure 2 illustrates representative linear RT-qPCR amplification plots showing the SARS-CoV-2
225 negative human saliva pool with the E gene amplifying earlier than in the SARS-CoV-2 positive
226 human saliva pool using the Omni RNA extraction method. Figure 2 demonstrates the false
227 positive amplification in the known SARS-CoV-2 negative human saliva using the Omni dPCR
228 method. Both the known SARS-CoV-2 positive human saliva pool and the known SARS-CoV-2
229 negative human saliva pool using the Omni dPCR method resulted in Cq value above 30. The
230 SalivaDirect extraction method and the Omni dPCR method both amplified higher than a Cq
231 value of 30 but the SalivaDirect extraction method did not show amplification in the known

232 SARS-CoV-2 negative human saliva pool. Four independent replicate experiments using
 233 different reagents each time showed the same results.
 234 Experiment 2 tracked the variant distribution of SARS-CoV-2 that occurred during the spring
 235 semester of 2021 at the University of Tennessee, Knoxville campus. Table 3 outlines the various
 236 deletions/mutations found in the variants of interest detected by PKamp VariantDirect SARS-
 237 CoV-2 RT-PCR Assay kit with Table 4 showing the results of the variant tests for the pools used
 238 in this study. Figure 3 demonstrates how the SARS-CoV-2 variant prevalence changed over
 239 time. Early in the spring semester (mid-March), almost all positive pools were caused by the
 240 original wild type of the SARS-CoV-2 virus. Mid to late spring semester (mid-March to the end
 241 of April), a shift in the SARS-CoV-2 variant was observed from wild type to mostly the Alpha
 242 variant (UK strain). Of the 210 human saliva pools subjected to variant testing, only 18 pools
 243 failed to be identified with the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit
 244 combinations used in this study. The mutations of the SARS-CoV-2 variants found in the 18
 245 pools that failed to be identified with the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit
 246 combinations are listed in Table 4.

Variant	ORF1a					
	H69/V70 deletion	L242/L244 deletion	3675/3677 deletion	L452R	E484K	E484Q
Wild Type	-	-	-	-	-	-
Alpha	+	-	+	-	-	-
Beta	-	+	+	-	+	-
Gamma	-	-	+	-	+	-
Delta	-	-	-	+	-	-

247 **Table 3.** SARS-Cov-2 variants showing the deletions characteristic for each variant [reference?
 248 where did this information come from?]. Presence of the mutation is indicated by (+) and
 249 absence of the mutation is indicated by (-).

Sample	ORF1a					
	H69/V70 deletion	L242/L244 deletion	3675/3677 deletion	L452R	E484K	E484Q
Pool 21	+	-	-	-	-	-

Pool 22	+	-	?	-	-	-
Pool 23	+	-	?	-	-	-
Pool 24	+	-	?	-	-	-
Pool 25	+	-	?	-	-	-
Pool 26	?	+	-	-	-	-
Pool 27	+	-	-	-	-	-
Pool 28	-	-	?	-	-	-
Pool 29	+	-	-	-	-	-
Pool 30	+	-	-	-	-	-
Pool 31	+	-	?	-	-	-
Pool 32	?	-	-	-	-	-
Pool 33	+	-	?	-	-	-
Pool 34	+	-	?	-	-	-
Pool 35	+	-	?	-	-	-
Pool 36	+	-	?	-	-	-
Pool 37	+	-	?	-	-	-
Pool 38	+	-	?	-	-	-

250 **Table 4.** Mutations present in samples with unidentified variants after both combinations D and
 251 F of the PKamp VariantDetect SARS-CoV-2 RT-PCR assay kit tests were performed. Presence
 252 of the mutation is indicated by (+) and absence of the mutation is indicated.

253

254 **Figure 3.** SARS-CoV-2 variant distribution across the University of Tennessee campus in spring
 255 2021. The asterisk (*) depicts the week that spring break usually occurs.

256

257 **Discussion:**

258 As illustrated in Figure 2, we noted that the Omni Direct-to-PCR (dPCR) method resulted in
 259 false positive amplification of the SARS-CoV-2 E gene in known SARS-CoV-2 negative human
 260 saliva pools. Both the known SARS-CoV-2 positive pool and the known negative pool using
 261 the Omni dPCR method showed amplification while the SalivaDirect extraction method did not
 262 show amplification in the known negative human saliva pool. A plausible explanation of the
 263 observations is nonspecific amplification or artifacts in the known SARS-CoV-2 negative human
 264 saliva that cause the observed false positive results. These artifacts can be caused by an

265 imbalance between primers, template and non-template RNA concentrations [14]. The negative
266 control for the Omni dPCR method showed no amplification, which leads us to attribute the
267 amplification of the E gene in the SARS-CoV-2 negative human saliva samples to the Omni
268 dPCR method itself. The test was repeated 4 separate times with new reagents each time to
269 assure contamination was not the issue. Each repetition produced similar results. Contamination
270 of the kit was ruled out as a contributing factor from the manufacturer due to the quality control
271 metrics reported wherein, they demonstrated the absence of any RNA in the kits via PCR and gel
272 visualization prior to shipment.

273 In Experiment 2, the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit identified which
274 variant was present in the majority of human saliva pools collected on the University of
275 Tennessee, Knoxville campus during the spring of 2021. These results demonstrate the ability of
276 the variant detection kit to quickly detect and differentiate between SARS-CoV-2 variants.
277 Although we cannot make definite conclusions on the variants present in these 18 SARS-CoV-2
278 positive human saliva pools listed in Table 4, we are able to gain some valuable information. The
279 majority of these 18 pools show H69/V70 deletions which is characteristic of the Alpha variant
280 lineage. The ORF1a 3675/3677 deletion, which was not detected or did not meet kit
281 specifications, may be in a region of the gene that has been speculated to have higher mutation
282 rates. Mutations found in the S-protein and the ORF1a and ORF1b genes can alter the viral
283 attachment, fusogenicity and/or immunogenicity as well as interrupt the viral proofreading [15,
284 16]. It has been suggested that some mutations in the ORF1a and ORF1b regions that alter the
285 viral replication can increase down-stream mutations [15, 16]. By piecing this information
286 together, we can hypothesize that there may be a SARS-CoV-2 variant of the Alpha lineage, with
287 increased rates of mutation present in our sampling community. By monitoring the rate of these

288 mutations in the population, we can monitor the rate of transmission of this particular lineage and
289 potentially detect upcoming variants of interest.

290 It is interesting to note that there were no confirmed cases of the Delta variant on the University
291 of Tennessee, Knoxville campus during the testing period. Considering the increased
292 transmissibility, this variant was expected to be prevalent in the later months of the spring
293 semester. Future studies could investigate the timeline of this variant in surrounding
294 communities and allow a better understanding of the spread of the Delta variant on campus.

295
296 Before the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay kit combo F kit was available,
297 we attempted to identify variants using the GT Molecular RT-qPCR SARS-CoV-2 Delta Variant
298 Mutational Signature Assay Kit (Fort Collins, CO; SKU: 100172). We did not observe
299 amplification using this kit with any of the human saliva samples collected on campus.

300 Herein we successfully evaluated three qPCR-based assays for the detection of SARS-CoV-2
301 from saliva pooled samples obtained across the University of Tennessee, Knoxville campus in
302 early 2021. While evaluating the three methods, the Omni Direct-to-PCR method, SalivaDirect,
303 and the King Fisher extraction method, they were shown to have a greater than 80% agreement
304 between all methods when identifying SARS-CoV-2 positive saliva pools. Secondary to the
305 successful identification of SARS-CoV-2 in the pooled saliva samples, it was shown that the
306 mechanical homogenization technique utilized by the Omni dPCR method provided sufficient
307 viral lysis and exposure of the viral RNA to go directly into qPCR detection, bypassing
308 traditional extraction methods while maintaining sensitivity in comparison to two other
309 extraction-based methods evaluated. In addition to the evaluation of the three qPCR assays, the
310 saliva pools were tested using the PKamp VariantDetect SARS-CoV-2 RT-PCR Assay to track

311 the presence and proportionality of multiple variants of concern across the university's campus
312 during the spring 2021 semester. When evaluating variants, an observed shift from wild type to
313 alpha variant was seen surrounding spring break. This shift corresponds with a national trend
314 seen at that time as the alpha variant transitioned to becoming the dominant variant across the
315 US. An unidentified variant was seen as the semester progressed, but it is likely that that is the
316 emergence of a recombination seen following spring break with large portions of the student
317 body traveling and was an event that did not correspond with a variant of concern identified in
318 the utilized assay. Further evaluation of the unidentified variant could be considered for future
319 studies on the genomic diversity of SARS-CoV-2 across university populations. Overall, this
320 manuscript successfully demonstrates the ability of multiple commercially available assays to
321 successfully utilize pooled saliva samples for highly sensitive SARS-CoV-2 detection.

322

323 **Acknowledgments**

324 We acknowledge the University of Tennessee Office of Research and Engagement for providing
325 funding for this project and Omni International Inc, A PerkinElmer Company. Additionally, we
326 would like to acknowledge and thank Mr. Pete Tortorelli of Omni International for his continued
327 leadership and financial support of our research endeavors.

328 **Author Contributions**

329 Author contributions to this manuscript have been determined utilizing the CRediT criteria as
330 denoted below. **MR Poindexter:** conceptualization, data curation, formal analysis, investigation,
331 visualization, writing – original draft, writing – review and editing. **T Xu:** data curation, formal
332 analysis, methodology, investigation, visualization, writing – original draft, writing – review and
333 editing. **CM Swift:** data curation, formal analysis, visualization, writing – original draft, writing –
334 review and editing. **CM Proctor:** investigation, methodology, writing – review and editing. **F**
335 **Kara-Murdoch:** formal analysis, validation, writing – review and editing. **ZP Morehouse:**
336 conceptualization, methodology, writing – original draft, writing – review and editing. **GL Ryan:**
337 methodology, writing – review and editing. **FE Löffler:** conceptualization, formal analysis,
338 funding acquisition, investigation, methodology, project administration, resources, supervision,
339 writing – review and editing. **RJ Nash:** conceptualization, funding acquisition, investigation,
340 methodology, project administration, resources, supervision, writing – review and editing.

341 **Data Availability Statement**

342 All data pertaining to this study is presented and available in the manuscript without alterations or
343 restrictions.

344 **Funding**

345 All funding for this project was provided from internal funding sources. The University of
346 Tennessee Office of Research and Engagement provided internal funding to support the on campus
347 research efforts while Omni International Inc, A PerkinElmer Company provided resources and
348 internal funding to provide equipment and testing supplies to support this study.

349 **Conflicts of Interests**

350 Authors Caleb M Proctor, Gabriella L Ryan, and Rodney J Nash are all employed by Omni
351 International Inc, A PerkinElmer Company, which provided some funding and reagents for this
352 work. Author Zachary P Morehouse has a contractor association with Omni International Inc, A
353 PerkinElmer Company. Authors Caleb M Proctor, Zachary P Morehouse, and Rodney J Nash are
354 all named inventors on the patented Omni dPCR method described in this paper, however, they
355 have no financial ownership of the method and do not have any financial incentives for its success
356 or failure. The above authors attest that their relationship with Omni International Inc, A
357 PerkinElmer company has not influenced their work on this project, nor are they receiving any
358 incentive for the publication of this work. Authors Magen R Poindexter, Tingting Xu, Cynthia M
359 Swift, Fadime Kara-Murdoch, and Frank E Löffler have no conflicts of interests to report.




360

361 **References:**

- 362 1. Böger, B., et al., *Systematic review with meta-analysis of the accuracy of diagnostic tests*
363 *for COVID-19*. Am J Infect Control, 2021. **49**(1): p. 21-29.
- 364 2. Zapor, M., *Persistent Detection and Infectious Potential of SARS-CoV-2 Virus in Clinical*
365 *Specimens from COVID-19 Patients*. Viruses, 2020. **12**(12).
- 366 3. Hirotsu, Y., H. Mochizuki, and M. Omata, *Double-quencher probes improve detection*
367 *sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a*
368 *reverse-transcription polymerase chain reaction (RT-PCR) assay*. Journal of virological
369 *methods*, 2020. **284**: p. 113926-113926.

- 370 4. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-*
371 *PCR*. Euro surveillance : bulletin European sur les maladies transmissibles = European
372 communicable disease bulletin, 2020. **25**(3): p. 2000045.
- 373 5. Ash, K.T., et al., *Coding-Complete Genome Sequence of a SARS-CoV-2 Variant*
374 *Obtained from Raw Sewage at the University of Tennessee-Knoxville Campus*.
375 Microbiology Resource Announcements, 2021. **10**(47).
- 376 6. Kuchinski, K.S., A.N. Jassem, and N.A. Prystajecy, *Assessing oligonucleotide designs*
377 *from early lab developed PCR diagnostic tests for SARS-CoV-2 using the PCR_strainer*
378 *pipeline*. Journal of clinical virology : the official publication of the Pan American
379 Society for Clinical Virology, 2020. **131**: p. 104581-104581.
- 380 7. Chakraborty, C., et al., *Evolution, Mode of Transmission, and Mutational Landscape of*
381 *Newly Emerging SARS-CoV-2 Variants*. mBio, 2021. **12**(4): p. e0114021.
- 382 8. Chakraborty, D., A. Agrawal, and S. Maiti, *Rapid identification and tracking of SARS-*
383 *CoV-2 variants of concern*. The Lancet, 2021. **397**(10282): p. 1346-1347.
- 384 9. Ransom, E.M., et al., *Comparison of Extraction Methods and Thermocyclers for SARS-*
385 *CoV-2 Molecular Detection Using Clinical Specimens*. Journal of Clinical Microbiology,
386 2020. **58**(10): p. e01622-20.
- 387 10. Rodríguez Flores, S.N., et al., *Comparison Between a Standard and SalivaDirect RNA*
388 *Extraction Protocol for Molecular Diagnosis of SARS-CoV-2 Using Nasopharyngeal*
389 *Swab and Saliva Clinical Samples*. Frontiers in Bioengineering and Biotechnology, 2021.
390 **9**.
- 391 11. Morehouse, Z.P., et al., *Validation of a direct-to-PCR COVID-19 detection protocol*
392 *utilizing mechanical homogenization: A model for reducing resources needed for*
393 *accurate testing*. PLOS ONE, 2021. **16**(8): p. e0256316.
- 394 12. Vogels, C.B.F., et al., *SalivaDirect: A simplified and flexible platform to enhance SARS-*
395 *CoV-2 testing capacity*. Med (N Y), 2021. **2**(3): p. 263-280.e6.
- 396 13. Schoch, C.L., et al., *NCBI Taxonomy: a comprehensive update on curation, resources*
397 *and tools*. Database (Oxford), 2020. **2020**.
- 398 14. Ruiz-Villalba, A., et al., *Amplification of nonspecific products in quantitative polymerase*
399 *chain reactions (qPCR)*. Biomolecular detection and quantification, 2017. **14**: p. 7-18.
- 400 15. Pachetti, M., et al., *Emerging SARS-CoV-2 mutation hot spots include a novel RNA-*
401 *dependent-RNA polymerase variant*. Journal of Translational Medicine, 2020. **18**(1): p.
402 179.
- 403 16. Ilmjärv, S., et al., *Concurrent mutations in RNA-dependent RNA polymerase and spike*
404 *protein emerged as the epidemiologically most successful SARS-CoV-2 variant*. Scientific
405 Reports, 2021. **11**(1): p. 13705.




406



● Omni Direct-to-Saliva ▼ Proteinase K Extraction ■ KingFisher Extraction ◆ Positive Control

Figure 1

medRxiv preprint doi: <https://doi.org/10.1101/2022.05.11.22274949>; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



●— Omni Direct-to-PCR ●···· KingFisher Extraction ▼— SalivaDirect Extraction

Figure 2

Variant Distribution Over Time




Figure 3